Therapeutics Related News

Autolus Announces Publication of a Unique Therapeutic Approach for Treatment of Patients with T-Cell Lymphomas in Nature Medicine

London, 14 November 2017  - Autolus Limited, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, today announced the publication of an article in Nature Medicine describing a unique targeting strategy for the treatment [...]

By | November 14th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

ERS Genomics and Cellecta, Inc. Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and Services

DUBLIN, Ireland, and Mountain View, CA, November 10, 2017 - ERS Genomics Ltd. and Cellecta, Inc. announced today a non-exclusive license agreement to provide Cellecta with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property for use in informing research tools and services. [...]

By | November 12th, 2017|BioPharma & Healthcare, News, Therapeutics|

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

Nov 1, 2017 CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced that it has commenced an underwritten public offering of $150 million of [...]

By | November 1st, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Vedanta Biosciences to Advance Cancer Immunotherapy Candidates Based on Microbiome-Derived Live Biotherapeutics that Induce CD8+ T Cells

Company exclusively licensed key intellectual property from JSR Corporation in Japan, based on Dr. Kenya Honda’s discoveries IND filing for lead immuno-oncology candidate planned for 2018 November 01, 2017 03:00 AM Eastern Daylight Time - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, an [...]

By | November 1st, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma

SAN DIEGO, Oct. 26, 2017 — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, today announced that the California Institute for Regenerative Medicine (CIRM) awarded a $19.8 million grant to support the [...]

By | October 31st, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics

San Diego, Calif., October 31, 2017 – Arcturus Therapeutics, Inc., a leading RNA medicines company, and Synthetic Genomics, Inc. announced today that they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines and therapeutics in [...]